Celebrex was the first in a new, safer class of arthritis drugs called COX-2 inhibitors that, unlike older drugs, don't cause ulcers.

FORBES: Ready For Battle

Erbitux's rejection thrust Iressa into first place in the race to bring to market a new class of cancer drugs that disrupt cellular growth--without the wretched side effects of chemotherapy.

FORBES: A Homegrown Pipeline